PMID- 34815682
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220428
IS  - 1178-7007 (Print)
IS  - 1178-7007 (Electronic)
IS  - 1178-7007 (Linking)
VI  - 14
DP  - 2021
TI  - Fibrinogen to Albumin Ratio as an Independent Risk Factor for Type 2 Diabetic 
      Kidney Disease.
PG  - 4557-4567
LID - 10.2147/DMSO.S337986 [doi]
AB  - PURPOSE: Diabetic kidney disease (DKD) is an inflammatory disease. This study 
      aimed to investigate the association of fibrinogen to albumin ratio (FAR) with 
      DKD. PATIENTS AND METHODS: A total of 1022 type 2 diabetes mellitus (T2DM) 
      patients with DKD and 1203 T2DM patients without DKD were enrolled in this study. 
      Laboratory values including blood cell count, hemoglobin A1c, biochemical 
      parameters, and fibrinogen and albumin creatinine ratio were recorded. Patients 
      were classified according to tertile of admission FAR. Clinical parameters were 
      compared between groups. Logistic regression, linear regression, ROC analysis and 
      spline regression were carried out. RESULTS: FAR in the DKD group was 
      significantly higher than that in the non-DKD group. FAR had the highest odds 
      ratio as an independent risk factor for the development of DKD and the highest 
      area under ROC curve for predicting DKD compared with albumin (ALB) or fibrinogen 
      (FIB) alone. Simple linear regression analyses revealed a significant and linear 
      correlation of FAR with neutrophil and neutrophil-to-lymphocyte ratio. FAR was an 
      independent risk factor for development of DKD. Spline regression showed that 
      there was a significant linear association between DKD incidence and continuous 
      FAR value when it exceeded 67.3mg/g. CONCLUSION: FAR is a stronger independent 
      predictor of DKD than FIB and ALB. FAR is an independent risk factor for DKD 
      development when it exceeded 67.3mg/g. FAR might be one of novel diagnostic 
      biomarkers to predict and prevent DKD progression. However, a prospective study 
      to validate the prognostic model is still needed.
CI  - (c) 2021 Wang et al.
FAU - Wang, Kai
AU  - Wang K
AD  - Department of Endocrinology, Shanghai Fifth People's Hospital, Fudan University, 
      Shanghai, People's Republic of China.
AD  - Department of Respiratory and Critical Care Medicine, Shanghai Fifth People's 
      Hospital, Fudan University, Shanghai, People's Republic of China.
FAU - Xu, Wenjun
AU  - Xu W
AD  - Department of Nephrology, Zhejiang Kaihua County Hospital of Chinese Medicine, 
      Zhejiang, People's Republic of China.
FAU - Zha, Bingbing
AU  - Zha B
AD  - Department of Endocrinology, Shanghai Fifth People's Hospital, Fudan University, 
      Shanghai, People's Republic of China.
FAU - Shi, Jindong
AU  - Shi J
AD  - Department of Respiratory and Critical Care Medicine, Shanghai Fifth People's 
      Hospital, Fudan University, Shanghai, People's Republic of China.
FAU - Wu, Guowei
AU  - Wu G
AD  - Department of Nephrology, Zhejiang Kaihua County Hospital of Chinese Medicine, 
      Zhejiang, People's Republic of China.
FAU - Ding, Heyuan
AU  - Ding H
AUID- ORCID: 0000-0002-1574-8690
AD  - Department of Endocrinology, Shanghai Fifth People's Hospital, Fudan University, 
      Shanghai, People's Republic of China.
AD  - Department of Nephrology, Zhejiang Kaihua County Hospital of Chinese Medicine, 
      Zhejiang, People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20211115
PL  - New Zealand
TA  - Diabetes Metab Syndr Obes
JT  - Diabetes, metabolic syndrome and obesity : targets and therapy
JID - 101515585
PMC - PMC8605489
OTO - NOTNLM
OT  - diabetic kidney disease
OT  - fibrinogen to albumin ratio
OT  - inflammation
OT  - type 2 diabetes mellitus
COIS- The authors report no conflicts of interest in this work.
EDAT- 2021/11/25 06:00
MHDA- 2021/11/25 06:01
PMCR- 2021/11/15
CRDT- 2021/11/24 06:31
PHST- 2021/09/14 00:00 [received]
PHST- 2021/11/02 00:00 [accepted]
PHST- 2021/11/24 06:31 [entrez]
PHST- 2021/11/25 06:00 [pubmed]
PHST- 2021/11/25 06:01 [medline]
PHST- 2021/11/15 00:00 [pmc-release]
AID - 337986 [pii]
AID - 10.2147/DMSO.S337986 [doi]
PST - epublish
SO  - Diabetes Metab Syndr Obes. 2021 Nov 15;14:4557-4567. doi: 10.2147/DMSO.S337986. 
      eCollection 2021.